Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 499 across all filing types
Latest filing 2026-02-18 Regulatory Filings
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Hansa Biopharmas ansökan för biologisk medicinsk produkt (BLA) för imlifidase har accepterats av FDA
Regulatory Filings Classification · 95% confidence The document is a press release from Hansa Biopharma announcing that the FDA has accepted their Biologics License Application (BLA) for imlifidase. It details the regulatory milestone, provides context on the clinical trial (ConfIdeS), and includes standard corporate boilerplate information. It is not a full financial report, audit, or proxy statement, but rather a regulatory announcement regarding a product development milestone. Given the specific nature of the announcement (regulatory filing acceptance), it fits best under 'Regulatory Filings' (RNS) as it is a corporate announcement of a regulatory event.
2026-02-18 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive quarterly report (Q4 2025) for Hansa Biopharma. It contains detailed financial tables (income statement, cash flow, balance sheet items), management commentary on business performance, clinical pipeline updates, and strategic outlook. It is not a mere announcement of a report (RPA) or a simple earnings release (ER), as it provides substantive financial data and detailed operational analysis. Therefore, it is classified as an Interim/Quarterly Report. Q4 2025
2026-02-11 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report' and covers the period 'January - December 2025'. It contains comprehensive financial data, including revenue, expenses, loss from operations, and cash flow statements for Q4 and the full year. It also provides detailed business, clinical pipeline, and management updates. As it contains substantive financial statements and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q4 2025
2026-02-11 English
Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation
Regulatory Filings Classification · 95% confidence The document is a press release from Hansa Biopharma announcing the submission of a Biologics License Application (BLA) to the FDA. It is a corporate announcement regarding regulatory progress and clinical trial outcomes. It does not fit into specific categories like 10-K, CT, or IR, and is not a report publication announcement (RPA) as it is the primary announcement itself. Therefore, it falls under the general regulatory filing category.
2025-12-19 English
Hansa Biopharma lämnar in BLA-ansökan till FDA för imlifidase för desensitisering vid njurtransplantation
Regulatory Filings Classification · 95% confidence The document is a press release from Hansa Biopharma announcing the submission of a Biologics License Application (BLA) to the FDA for their drug imlifidase. It details the regulatory milestone, the clinical trial results (ConfIdeS study) supporting the application, and the company's request for priority review. As this is a formal announcement of a regulatory filing event rather than the filing itself, and it does not fit into specific categories like earnings or dividends, it is classified as a Regulatory Filing (RNS).
2025-12-19 Swedish
Hansa provides update on Pivotal Phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease
Regulatory Filings Classification · 95% confidence The document is a press release issued by Hansa Biopharma regarding the results of a Phase 3 clinical trial (GOOD-IDES-02). It details the trial's primary endpoint outcome, provides management commentary, and includes standard regulatory disclosure language (EU Market Abuse Regulation). As it is an initial announcement of clinical trial results rather than a full report or a regulatory filing for a specific corporate event, it falls under the category of a general regulatory announcement or press release.
2025-12-16 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.